Synthesis of gossypol atropisomers and derivatives and evaluation of their anti-proliferative and anti-oxidant activity

被引:65
作者
Dodou, K
Anderson, RJ
Lough, WJ
Small, DAP
Shelley, MD
Groundwater, PW
机构
[1] Univ Sunderland, Sunderland Pharm Sch, Sunderland SR1 3SD, Durham, England
[2] Stiefel Int R&D, Maidenhead SL6 8XY, Berks, England
[3] Velindre NHS Trust, Cardiff CF14 2TL, S Glam, Wales
关键词
gossypol; atropisomers; psoriasis; anti-oxidant; anti-proliferative;
D O I
10.1016/j.bmc.2005.04.026
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Gossypol 1, gossypolone 2, and a series of bis 3 and half Schiffs bases 4 of gossypol were synthesised and tested for anti-proliferative and anti-oxidant activity. (-)-Gossypol (-)-1 was the most potent inhibitor of the proliferation of the HPV-16 keratinocyte cell line (using an MTT viability assay) with a GI(50) of 4.8 mu M. The bis Schiffs base of (-)-gossypol with L-tyrosine ethyl ester (-)-3b was the most potent inhibitor of iron/ascorbate dependent lipid peroxidation (using the thiobarbituric acid test), with an IC50 of 11.7 mu M, with (-)-gossypol being the next most potent of the series, with an IC50 of 13.1 mu M. The results from these initial assays suggest that gossypol, as either a racemic mixture rac-1, or the individual atropisomers (-)-1 or (+)-1, has potential for the treatment of psoriasis. (c) 2005 Elsevier Ltd. All rights reserved.
引用
收藏
页码:4228 / 4237
页数:10
相关论文
共 40 条
[31]  
SI YK, 1987, SCI CHINA SER B, V30, P297
[32]   A PRELIMINARY CLINICAL-STUDY OF GOSSYPOL IN ADVANCED HUMAN CANCER [J].
STEIN, RC ;
JOSEPH, AEA ;
MATLIN, SA ;
CUNNINGHAM, DC ;
FORD, HT ;
COOMBES, RC .
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 1992, 30 (06) :480-482
[33]   INHIBITION OF CATECHOL-O-METHYLTRANSFERASE BY GOSSYPOL - THE EFFECT OF PLASMA-PROTEINS [J].
TANG, F ;
TSANG, AYF ;
LEE, C ;
WONG, PYD .
CONTRACEPTION, 1982, 26 (05) :515-519
[34]   Antioxidant potential of propylthiouracil in patients with psoriasis [J].
Utas, S ;
Köse, K ;
Yazici, C ;
Akdas, A ;
Kelestimur, F .
CLINICAL BIOCHEMISTRY, 2002, 35 (03) :241-246
[35]   Oral gossypol in the treatment of patients with refractory metastatic breast cancer: A phase I/II clinical trial [J].
Van Poznak, C ;
Seidman, AD ;
Reidenberg, MM ;
Moasser, MM ;
Sklarin, N ;
Van Zee, K ;
Borgen, P ;
Gollub, M ;
Bacotti, D ;
Yao, TJ ;
Bloch, R ;
Ligueros, M ;
Sonenberg, M ;
Norton, L ;
Hudis, C .
BREAST CANCER RESEARCH AND TREATMENT, 2001, 66 (03) :239-248
[36]   Gossypol: Prototype of inhibitors targeted to dinucleotide folds [J].
Vander Jagt, DL ;
Deck, LM ;
Royer, RE .
CURRENT MEDICINAL CHEMISTRY, 2000, 7 (04) :479-498
[37]  
WACKVOM LTD, 2003, Patent No. 6608107
[39]   Gossypol modification of Ala-1 of secreted phospholipase A(2): A probe for the kinetic effects of sulfate glycoconjugates [J].
Yu, BZ ;
Rogers, J ;
Ranadive, G ;
Baker, S ;
Wilton, DC ;
ApitzCastro, R ;
Jain, MK .
BIOCHEMISTRY, 1997, 36 (41) :12400-12411
[40]   Apoptotic effect of gossypol on human lymphocytes [J].
Yurtcu, E ;
Ergun, MA ;
Menevse, A .
CELL BIOLOGY INTERNATIONAL, 2003, 27 (09) :791-794